CartiNova's Laser Focus on a Non-Surgical Orthopedic Future

ATLANTA, GA – March 03, 2026 – In a strategic move poised to challenge the conventions of orthopedic medicine, Atlanta-based regenerative platform CartiNova has enlisted the integrated marketing and PR firm Trevelino/Keller to spearhead its national expansion. The partnership signals a significant push to bring CartiNova's minimally invasive alternatives to knee and spine surgery into the mainstream, leveraging a combination of advanced technology and aggressive communications strategy.

Founded by Dr. Trevor Turner, a nationally recognized physician in regenerative orthopedics, CartiNova is moving to disrupt what its founder calls the "traditional surgery-first approach." At a time when the global market for minimally invasive orthopedic procedures is projected to grow at a compound annual rate of 9%, CartiNova's model represents a compelling vision of the future. The company has tasked Trevelino/Keller, a firm with a documented history of elevating disruptive brands, with a comprehensive mandate: to build its digital presence, manage its social media, lead public relations, and execute a performance-based SEO strategy to carve out a prominent space in a competitive healthcare landscape.

The Integrated Technology Platform

CartiNova's approach is not built on a single innovation but on the integration of three distinct pillars: fractional laser technology, regenerative biologics, and data-driven analytics. This multi-modal system is designed to offer a highly personalized treatment that addresses the root cause of joint degradation rather than just masking symptoms.

The centerpiece of its technological arsenal is the Regenelase laser system, a device that has received FDA clearance for specific surgical applications, including the cutting and coagulation of soft tissue like meniscus cartilage, as well as for providing temporary pain relief. The system's 1550nm laser creates microscopic zones of thermal effect within cartilage, a technique intended to stimulate the body's natural healing cascade and promote collagen production. This nano-fractional approach borrows precision from advanced dermatology and applies it to musculoskeletal health.

This laser treatment is combined with regenerative biologics, such as Platelet-Rich Plasma (PRP) and Bone Marrow Concentrate (BMC). It is crucial to note that while CartiNova states its use of these biologics is compliant with FDA regulatory guidance, the therapies themselves are not FDA-approved for the specific treatment of arthritis or cartilage regeneration. This distinction is common in the rapidly evolving field of regenerative medicine, where clinical practice often outpaces the lengthy regulatory approval process. The clinic's philosophy is that combining these biologics with laser therapy creates a synergistic effect, enhancing the body's ability to repair damaged tissue.

The third pillar is a sophisticated data analytics engine. CartiNova's proprietary "BioProfile" synthesizes a patient's whole genome sequencing, advanced biomarkers, and imaging with AI to create a deeply personalized treatment plan. Post-procedure, recovery is guided by OxeFit analytics, a system that provides objective movement data, giving patients access to the kind of performance insights typically reserved for elite athletes.

A New Model for Patient Care and Accessibility

Beyond the technology, CartiNova is championing a patient-centric delivery model. The practice emphasizes individualized care plans tailored not just to a patient's anatomy but also to their activity level and long-term performance goals. This stands in contrast to what some perceive as the one-size-fits-all nature of traditional orthopedic pathways.

"CartiNova was built to disrupt the traditional surgery-first approach in orthopedics by offering precise, image-guided treatments that address the health of the tissue itself, not just the symptoms," Dr. Turner explained in a statement. His own background lends significant credibility to the venture. A board-certified physician, Dr. Turner trained for four years under the legendary sports surgeon Dr. James Andrews and previously served as the Director of the Center for Orthobiologics at Georgia Bone & Joint.

To broaden its reach beyond the Atlanta metro area, CartiNova has adopted a medical-travel-friendly model, actively welcoming patients from across the country. However, this accessibility comes with a significant caveat: cost. Like most advanced regenerative medicine treatments, CartiNova's procedures are generally not covered by insurance, as they are often classified as "experimental" or "investigational" by payors. This means patients must bear the full cost out-of-pocket, which can range from several thousand to tens of thousands of dollars, creating a substantial barrier for many individuals seeking alternatives to surgery.

Marketing a Medical Revolution

The decision to hire Trevelino/Keller underscores the unique challenges of marketing a disruptive medical technology. Building trust with both patients and the wider medical community is paramount, especially when treatments involve out-of-pocket costs and novel technologies. Trevelino/Keller's experience in the healthcare sector, including a top ranking in Atlanta healthcare PR by O'Dwyer's, was a key factor in its selection.

"I chose Trevelino/Keller for their experience in medical technology and disruptive companies," Dr. Turner stated. "Their strategic approach... aligned well with my vision to make CartiNova a differentiated brand in orthopedics."

The marketing firm's task is multifaceted. It involves educating the public about a complex scientific process, validating the technology's potential through targeted media outreach, and building a digital ecosystem that can attract and convert patients looking for non-surgical options. The personal endorsement from Dean Trevelino, co-CEO of the marketing agency, adds a unique layer to the partnership.

"As a patient of Dr. Turner, I appreciate his commitment to improving patients' quality of life through a non-invasive approach," shared Trevelino. "Innovative thinking and technology, such as the Regenelase laser used at CartiNova, help you realize you don't need to retire the activities of your 30s or 40s when those years are in the rearview mirror."

As this partnership gets underway, its success will be measured not only in website traffic and media placements but in its ability to shift perceptions. The collaboration between CartiNova and Trevelino/Keller represents a calculated effort to accelerate the adoption of a new paradigm in joint health, one where data, lasers, and the body's own healing potential may one day make the surgeon's knife a last resort rather than a first option.